Fertility and Sterility
Volume 91, Issue 6 , Pages 2437-2444 , June 2009

Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection–embryo transfer cycle

  • Korhan Kahraman, M.D.

      Affiliations

    • Ankara University School of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey
    • Corresponding Author InformationReprint requests: Korhan Kahraman, M.D., Ankara Üniversitesi Tıp Fakültesi Kadın, Hastalıkları ve Doğum Anabilim Dalı, 06100, Cebeci, Ankara, Turkey (FAX: 90-312-320-35-53).
    • ,
  • Bulent Berker, M.D.

      Affiliations

    • Ankara University School of Medicine, Division of Reproductive Medicine and Gynecologic Endocrinology, Ankara, Turkey
    • ,
  • Cem Somer Atabekoglu, M.D.

      Affiliations

    • Ankara University School of Medicine, Division of Reproductive Medicine and Gynecologic Endocrinology, Ankara, Turkey
    • ,
  • Murat Sonmezer, M.D.

      Affiliations

    • Ankara University School of Medicine, Division of Reproductive Medicine and Gynecologic Endocrinology, Ankara, Turkey
    • ,
  • Esra Cetinkaya, M.D.

      Affiliations

    • Ankara University School of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey
    • ,
  • Rusen Aytac, M.D.

      Affiliations

    • Ankara University School of Medicine, Division of Reproductive Medicine and Gynecologic Endocrinology, Ankara, Turkey
    • ,
  • Hakan Satiroglu, M.D.

      Affiliations

    • Ankara University School of Medicine, Division of Reproductive Medicine and Gynecologic Endocrinology, Ankara, Turkey

Received 26 November 2007 ,Revised 23 March 2008 ,Accepted 24 March 2008.

References 

  1. Tarlatzis BC, Zepiridis L, Grimbizis G, Bontis J. Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum Reprod Update. 2003;9:61–76
  2. Surrey ES, Schoolcraft WB. Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques. Fertil Steril. 2000;73:667–676
  3. Bukulmez O, Arici A. Assessment of ovarian reserve. Curr Opin Obstet Gynecol. 2004;16:231–237
  4. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12:685–718
  5. Mahutte NG, Arici A. Poor responders: does the protocol make a difference?. Curr Opin Obstet Gynecol. 2002;14:275–281
  6. Shanbhag S, Aucott L, Bhattacharya S, Hamilton MA, McTavish AR. Interventions for “poor responders” to controlled ovarian hyperstimulation (COH) in in-vitro fertilisation (IVF). Cochrane Database Syst Rev. 2007;(1):CD004379
  7. Scott RT, Navot D. Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization. Fertil Steril. 1994;61:880–885
  8. Schoolcraft W, Schlenker T, Gee M, Stevens J, Wagley L. Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol. Fertil Steril. 1997;67:93–97
  9. Surrey ES, Bower J, Hill DM, Ramsey J, Surrey MW. Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization. Fertil Steril. 1998;69:419–424
  10. Akman MA, Erden HF, Tosun SB, Bayazit N, Aksoy E, Bahceci M. Addition of GnRH antagonist in cycles of poor responders undergoing IVF. Hum Reprod. 2000;15:2145–2147
  11. Howles CM, Macnamee MC, Edwards RG. Short term use of an LHRH agonist to treat poor responders entering an IVF programme. Hum Reprod. 1987;2:655–656
  12. Padilla SL, Dugan K, Maruschak V, Shalika S, Smith RD. Use of the flare-up protocol with high dose follicle stimulating hormone and human menopausal gonadotropins for in vitro fertilization in poor responders. Fertil Steril. 1996;65:796–799
  13. San Roman G, Surrey E, Judd H, Kerin J. A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin-releasing hormone agonist for in vitro fertilization. Fertil Steril. 1992;58:744–749
  14. Brzyski R, Muasher S, Droesch K, Simonetti S, Jones G, Rosenwaks Z. Follicular atresia associated with concurrent initiation of gonadotropin releasing hormone agonist and follicle-stimulating hormone for oocyte recruitment. Fertil Steril. 1988;50:917–921
  15. Craft I, Gorgy A, Hill J, Menon D, Podsiadly B. Will GnRH antagonists provide new hope for patients considered “difficult responders” to GnRH agonist protocols?. Hum Reprod. 1999;14:2959–2962
  16. Cheung LP, Lam PM, Lok IH, Chiu TT, Yeung SY, Tjer CC, et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Hum Reprod. 2005;20:616–621
  17. Coperman AB. Antagonists in poor-responder patients. Fertil Steril. 2003;80:16–24
  18. Hernandez ER. Embryo implantation: the rubicon for GnRH antagonists. Hum Reprod. 2000;15:1211–1216
  19. Borm G, Mannaerts B. The European Orgalutran Study Group. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod. 2000;15:1490–1498
  20. Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, et al. North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril. 2001;75:38–45
  21. Felberbaum RE, Diedrich K. Gonadotrophin-releasing hormone antagonists: will they replace the agonists?. Reprod Biomed Online. 2003;6:43–53
  22. Akman MA, Erden HF, Tosun SB, Bayazit N, Aksoy E, Bahceci M. Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Hum Reprod. 2001;16:868–870
  23. Schmidt DW, Bremner T, Orris JJ, Maier DB, Benadiva CA, Nulsen JC. A randomized prospective study of microdose leuprolide versus ganirelix in in vitro fertilization cycles for poor responders. Fertil Steril. 2005;83:1568–1571
  24. Eskandar M, Jaroudi K, Jambi A, Archibong EI, Coskun S, Sobande AA. Is recombinant follicle-stimulating hormone more effective in IVF poor responders than human menopausal gonadotrophins?. Med Sci Monit. 2004;10:16–19
  25. Berkkanoglu M, Isikoglu M, Aydın D, Ozgur K. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders. Fertil Steril. 2007;88:665–669
  26. Cedrin-Durnerin I, Grange-Dujardin D, Laffy A, Parneix I, Massin N, Galey J, et al. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2004;19:1979–1984
  27. De placido G, Mollo A, Clarizia R, Strina I, Conforti S, Alviggi C. Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response. Fertil Steril. 2006;85:247–250
  28. Ulug U, Ben-Shlomo I, Turan E, Erden HF, Akman MA, Bahceci M. Conception rates following assisted reproduction in poor responder patients: a retrospective study in 300 consecutive cycles. Repro Biomed Online. 2003;6:439–443

 K.K. has nothing to disclose. B.B. has nothing to disclose. C.S.A. has nothing to disclose. M.S. has nothing to disclose. E.C. has nothing to disclose. R.A. has nothing to disclose. H.S. has nothing to disclose.

PII: S0015-0282(08)00727-9

doi: 10.1016/j.fertnstert.2008.03.057

Fertility and Sterility
Volume 91, Issue 6 , Pages 2437-2444 , June 2009

Article Tools